We hypothesized that increasing access to care through Medicaid expansion would be associated with increased prostate cancer treatment at a population level for men diagnosed with higher-risk prostate tumors (Gleason grade group [GG] 3-5; GG 2 with prostate-specific antigen (PSA) level ≥10 ng/mL [to convert to micrograms per liter, multiply by 1.0]; or GG 1 with PSA level >20 ng/mL) that would result in definitive treatment.20 To test this, we used cancer registry data to compare patterns of prostate cancer treatment in states that did and did not expand Medicaid coverage. The gene discussed is KLK3; the disease is prostate carcinoma.